AR and breast cancer: In ER-negative (ER−) breast cancer, the activation of AR leads to the upregulation of Wnt and epidermal growth factor 2 (HER2) protumorigenic signaling pathway by increasing the transcription of Wnt family member 7B and epidermal growth factor 3 (HER3) (53).